US FDA approves Celltrion's Remicade biosimilar

By Melissa Fassbender contact

- Last updated on GMT

The biosimilar is expected to be launched later this year.
The biosimilar is expected to be launched later this year.

Related tags: Infliximab, Ulcerative colitis

The FDA has approved its first biosimilar mAb, Remsima – a Remicade biosimilar from Celltrion.

The approval​ follows the agency’s recommendation made in February of this year.

As Biopharma-Reporter previously reported, Remsima has already been launched in several European markets and is also sold by Hospira, now a Pfizer company​, under the name Inflectra.

The introduction of high-quality, effective biosimilars provides an opportunity to expand access to important medicines​,” said Salomon Azoulay, MD, senior vice president and chief medical officer, Pfizer Global Established Pharma Business.

As a leading global biologics company with several biosimilar products in our pipeline, we appreciate the significance of this milestone in developing a pathway for biosimilars to come to market in the U.S., and in helping advance their adoption in the healthcare system​.”

The monoclonal antibody (mAb) is biosimilar to Janssen Biotech’s Remicade, which was first licensed in 1998 for several indications, including Crohn's, ulcerative colitis, and rheumatoid arthritis, among others.

Per the FDA’s release, the approval was based on evidence that included structural and functional characterization, animal study data, human pharmacokinetic and pharmacodynamics data, clinical immunogenicity data, and other clinical safety and effectiveness data, all of which demonstrated that Inflectra was in fact biosimilar to Remicade.

Our experience in other markets across the globe demonstrates that biosimilars can be a welcome option for patients, physicians and other​s,” said Jenny Alltoft, head of global biosimilars, Pfizer Inc. “Pfizer is proud to play a leading role in preparing the U.S. market for biosimilars. We are committed to bringing these important medicines to patients in the U.S. as quickly as possible.

According to Pfizer, Inflectra's launch timeline will depend on several factors, including marketplace dynamics and intellectual property considerations; however the company is preparing for its launch plans scheduled for 2016.

Related news

Show more

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Related suppliers

Follow us


View more